|
14 Sep 2020 |
Neogene Therapeutics Raises $110 Million Series A Financing to Develop Next-Generation Fully Personalized Neo-Antigen T Cell Receptor (TCR) Therapies
|
|
14 Sep 2020 |
HiFiBiO Therapeutics Announces a Global Strategic Partnership With ABL Bio for the Co-Development of a SARS-CoV-2 Neutralizing Antibody
|
|
14 Sep 2020 |
Phase II trial results demonstrated improvement in cognition with BI 425809 in adult patients with schizophrenia
|
|
14 Sep 2020 |
Escient Pharmaceuticals Raises $77.5 Million Series B Round and Initiates a Phase 1/1b Clinical Trial of EP547, a MRGPR-targeted Therapy to Treat Cholestatic and Uremic Pruritus
|
|
14 Sep 2020 |
Seattle Genetics and Merck Announce Two Strategic Oncology Collaborations
|
|
14 Sep 2020 |
Gannex Filed US IND for Its NASH Drug ASC42, an FXR Agonist
|
|
14 Sep 2020 |
Alzprotect Forges Ahead with First Patients Enrolled in Phase 2a Study in Progressive Supranuclear Palsy (PSP)
|
|
14 Sep 2020 |
FDA Grants Dupixent® (dupilumab) Breakthrough Therapy Designation for Eosinophilic Esophagitis
|
|
14 Sep 2020 |
Novartis reports positive topline results from the first Phase III trial of Beovu® versus aflibercept in patients with diabetic macular edema (DME)
|
|
14 Sep 2020 |
Molecular Partners Completes GMP Manufacturing of Anti-COVID-19 DARPin® Candidate MP0420 for Clinical Use
|
|
14 Sep 2020 |
Gilead Sciences to Acquire Immunomedics
|
|
13 Sep 2020 |
Pfizer and BioNTech Propose Expansion of Pivotal COVID-19 Vaccine Trial
|
|
12 Sep 2020 |
COVID-19 vaccine AZD1222 clinical trials resumed in the UK
|
|
12 Sep 2020 |
Prasinezumab Slows Progression on Measures of Parkinson’s Disease in Phase 2 Study
|
|
12 Sep 2020 |
Keros Therapeutics Presents Results from Preclinical Studies Investigating KER-012 at the American Society for Bone and Mineral Research 2020 Annual Meeting
|
|
12 Sep 2020 |
Partner Therapeutics Announces Start of Phase 3 Portion of Clinical Study of Leukine® in Combination with Ipilumimab and Nivolumab in Front Line Treatment of Melanoma
|
|
12 Sep 2020 |
REYVOW™ (lasmiditan) C-V Demonstrated Pain Freedom from Migraine Attacks At 60 Minutes and Up to 48 Hours in New Phase 3 Study
|
|
12 Sep 2020 |
Neurocrine Biosciences and Voyager Therapeutics Present New Long-Term Three-Year Data Demonstrating that One-Time Treatment with an Investigational Gene Therapy Showed Sustained Improvement in Motor Function in Patients with Parkinson's Disease
|
|
12 Sep 2020 |
Neurocrine Biosciences Presents New Data Analyses Demonstrating Efficacy of FDA-Approved Once-Daily ONGENTYS® (opicapone) in Patients with Parkinson's Disease at the MDS Virtual Congress 2020
|
|
12 Sep 2020 |
Celltrion Announces Positive Interim Results From Phase I Trial of CT-P59, an Anti-COVID-19 Monoclonal Antibody Treatment Candidate
|
